Wednesday, July 8, 2026

Drug profile · INN

sotalol hydrochloride

sotalol hydrochloride (SORINE) is a beta-2 adrenergic receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 5
Pipeline programs 4
News articles 0
Drug details — sotalol hydrochloride
US status
approved
Class
Route
ORAL
Patents
5
Programs
4
Data quality
0.89

Quick answer

sotalol hydrochloride (SORINE) is a beta-2 adrenergic receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sotalol hydrochloride
Brand SORINE
Mechanism Beta-2 adrenergic receptor antagonist
Target Beta-1 adrenergic receptor
Route ORAL
Formulation SOLUTION

Mechanism of action

Beta-2 adrenergic receptor antagonist

Primary target: Beta-1 adrenergic receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. APHP230836 Phase 3 · PARItec · Patients presenting to ENT emergencies with a unilateral sud
  2. AC102-201 Phase 2 · Anaxis Pharma · Idiopathic Sudden Sensorineural Hearing Loss
  3. PIPE-505 Phase 2 · Contineum Therapeutics · Sensorineural Hearing Loss
  4. Gastrodin Injection Unknown · First People's Hospital · Sensorineural Hearing Loss

Related & competitor drugs

  1. acebutolol hydrochloride Beta-1 adrenergic receptor antagonist
  2. atenolol Beta-1 adrenergic receptor antagonist
  3. bisoprolol fumarate Beta-1 adrenergic receptor antagonist
  4. dobutamine hydrochloride Beta-1 adrenergic receptor agonist
  5. dopamine hydrochloride Cardiovascular system (C01)
  6. esmolol hydrochloride Beta-2 adrenergic receptor antagonist
  1. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11771671

    Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10653652

    Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 6649621

    Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms

    Expires Mon Nov 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  5. US 6177434

    Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms

    Expires Mon Jan 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is sotalol hydrochloride?

sotalol hydrochloride (SORINE) is a beta-2 adrenergic receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sotalol hydrochloride?

SORINE is a marketed brand name for sotalol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sotalol hydrochloride?

sotalol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.